GlassScriptPhysician profile
Robin Renee Eldib
NPI 1619947710
$512.44
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $154.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $141.65 | 2021-2022 | |
| Abbvie INC. | $134.51 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.07 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $25.57 | 2021-2022 | |
| Ibsa Pharma INC. | $18.34 | 2021 | |
| Neos Therapeutics, LP | $18.22 | 2022 | |
| Abbott Laboratories | $16.60 | 2021 | |
| Lilly USA, LLC | $14.80 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.16 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.86 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.24 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Eldib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.